Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Landy, J ^a,b   Walker, A W ^c,d   Li, J V ^b   Al Hassi, H O ^b   Ronde, E ^b   English, N R ^b   Mann, E R ^b   Bernardo, D ^b   McLaughlin, S D ^e   Parkhill, J ^c   Ciclitira, P J ^f   Clark, S K ^a   Knight, S C ^b   Hart, A L ^a,b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d ROWETT RESEARCH INSTITUTE   (United Kingdom)

^e BOURNEMOUTH UNIVERSITY   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CHRONIC DISEASE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; METABOLOMICS; MICROBIOLOGY; MIDDLE AGED; POUCHITIS; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; CHRONIC DISEASE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; METABOLOMICS; MIDDLE AGED; POUCHITIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84939203705     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12955     Document Type: Article

References (63)

1. Sartor, R. Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology 134, 577-594, doi: 10.1053/j.gastro.2007.11.059 (2008).
2. Nicholson, J. K. et al. Host-gut microbiota metabolic interactions. Science 336, 1262-1267, doi: 10.1126/science.1223813 (2012).
3. Holmes, E. et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 4, 137rv136, doi: 10.1126/ scitranslmed.3004244 (2012).
4. Hedin, C., Whelan, K. & Lindsay, J. O. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proceedings of the Nutrition Society 66, 307-315, doi: 10.1017/s0029665107005563 (2007).
5. Tannock, G. W. et al. Comprehensive analysis of the bacterial content of stool from patients with chronic pouchitis, normal pouches, or familial adenomatous polyposis pouches. Inflamm Bowel Dis 18, 925-934, doi: 10.1002/ibd.21936 (2012).
6. McLaughlin, S. D. et al. The Bacteriology of Pouchitis. Annals of Surgery 252, 90-98, doi: 10.1097/SLA.0b013e3181e3dc8b (2010).
7. Mizoguchi, E. et al. Characterization of the Gut-Associated Microbiome in Inflammatory Pouch Complications Following Ileal Pouch-Anal Anastomosis. PLoS One 8, e66934, doi: 10.1371/journal.pone.0066934 (2013).
8. Holubar, S. D., Cima, R. R., Sandborn, W. J. & Pardi, D. S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev, CD001176, doi: 10.1002/14651858.CD001176.pub2 (2010).
9. Gionchetti, P. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 13, 713-718 (1999).
10. Gionchetti, P. et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124, 1202-1209 (2003).
11. Gionchetti, P. et al. Oral Bacteriotherapy as Maintenance Treatment in Patients With Chronic Pouchitis: A Double-Blind, Placebo-Controlled Trial. Gastroenterology 119, 305-309, doi: 10.1053/gast.2000.9370 (2000).
12. Mimura, T. et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108-114 (2004).
13. Gionchetti, P. et al. High-Dose Probiotics for the Treatment of Active Pouchitis. Diseases of the Colon & Rectum 50, 2075-2084, doi: 10.1007/s10350-007-9068-4 (2007).
14. Van Assche, G. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis 7, 1-33, doi: 10.1016/j.crohns.2012.09.005 (2013).
15. McLaughlin, S. D. et al. Extended spectrum beta-lactamase-producing bacteria and Clostridium difficile in patients with pouchitis. Aliment Pharmacol Ther 32, 664-669, doi: 10.1111/j.1365-2036.2010.04401.x (2010).
16. Shen, B. et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 22, 721-728, doi: 10.1111/j.1365-2036.2005.02642.x (2005).
17. McLaughlin, S. D., Johnson M. W., Clark S. K., Tekkis P. P., Ciclitira P. J. & Nicholls R. J. Clinical experience with VSL#3 in patients with Chronic pouchitis. Gut 57, 1-4 (2008).
18. van Nood, E. et al. Duodenal Infusion of Donor Feces for RecurrentClostridium difficile. New England Journal of Medicine, 130116140046009, doi: 10.1056/NEJMoa1205037 (2013).
19. Vrieze, A. P. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity\par in individuals with metabolic syndrome.\par. Gastroenterology\par 143\par, 913-916 e917\par, doi: 10.1053/j.gastro.2012.06.031 (2012).
20. Grehan, M. J. et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44, 551-561, doi: 10.1097/MCG.0b013e3181e5d06b (2010).
21. Borody, T. J., Warren, E. F., Leis, S., Surace, R. & Ashman, O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37, 42-47 (2003).
22. Borody, T. J. et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 150, 604 (1989).
23. Bennet, J. D. & Brinkman, M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1, 164 (1989).
24. Angelberger, S. et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108, 1620-1630, doi: 10.1038/ajg.2013.257 (2013).
25. Kump, P. K. et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19, 2155-2165, doi: 10.1097/MIB.0b013e31829ea325 (2013).
26. Moayyedi, P. et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology, doi: 10.1053/j.gastro.2015.04.001 (2015).
27. Rossen, N. G. et al. Findings from a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis. Gastroenterology, doi: 10.1053/j.gastro.2015.03.045 (2015).
28. Stagg, A. J., Hart, A. L., Knight, S. C. & Kamm, M. A. Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity. Best Pract Res Clin Gastroenterol 18, 255-270, doi: 10.1016/j. bpg.2003.10.004 (2004).
29. Hart, A. et al. Characteristics of Intestinal Dendritic Cells in Inflammatory Bowel Diseases. Gastroenterology 129, 50-65, doi: 10.1053/j.gastro.2005.05.013 (2005).
30. Hart, A. L. et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53, 1602-1609, doi: 10.1136/gut.2003.037325 (2004).
31. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J. & Knight, S. C. Mechanisms of action of probiotics: Recent advances. Inflammatory Bowel Diseases 15, 300-310, doi: 10.1002/ibd.20602 (2009).
32. Lindsay, J. O. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348-355, doi: 10.1136/gut.2005.074971 (2006).
33. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105, 16731-16736, doi: 10.1073/pnas.0804812105 (2008).
34. Eisen, J. A., Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. PLoS Biology 6, e280, doi: 10.1371/journal.pbio.0060280 (2008).
35. Kohyama, A. et al. Bacterial population moves toward a colon-like community in the pouch after total proctocolectomy. Surgery 145, 435-447, doi: 10.1016/j.surg.2008.12.003 (2009).
36. Scarpa, M. et al. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 150, 56-67, doi: 10.1016/j.surg.2011.02.009 (2011).
37. Giaffer, M. H., Holdsworth, C. D. & Duerden, B. I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33, 646-650 (1992).
38. Pilarczyk-Zurek, M. et al. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol 13, 61, doi: 10.1186/1471-230x-13-61 (2013).
39. Gosselink, M. P. et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 47, 1519-1525, doi: 10.1007/s10350-004-0623-y (2004).
40. Png, C. W. et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105, 2420-2428, doi: 10.1038/ajg.2010.281 (2010).
41. Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15, 1183-1189, doi: 10.1002/ ibd.20903 (2009).
42. Marchesi, J. R. et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6, 546-551, doi: 10.1021/pr060470d (2007).
43. Machiels, K. et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, doi: 10.1136/gutjnl-2013-304833 (2013).
44. Weiss, G. A., Chassard, C. & Hennet, T. Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice. Br J Nutr 111, 1602-1610, doi: 10.1017/s0007114513004200 (2014).
45. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180, doi: 10.1038/nature09944 (2011).
46. Gorkiewicz, G. et al. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One 8, e55817, doi: 10.1371/ journal.pone.0055817 (2013).
47. Lawley, T. D. & Walker, A. W. Intestinal colonization resistance. Immunology 138, 1-11, doi: 10.1111/j.1365-2567.2012.03616.x (2013).
48. Aas, J., Gessert, C. E. & Bakken, J. S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36, 580-585, doi: 10.1086/367657 (2003).
49. MacConnachie, A. A., Fox, R., Kennedy, D. R. & Seaton, R. A. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102, 781-784, doi: 10.1093/qjmed/hcp118 (2009).
50. Kunde, S. et al. Safety, Tolerability, and Clinical Response after Fecal Transplantation in Children and Young Adults with Ulcerative Colitis. J Pediatr Gastroenterol Nutr, doi: 10.1097/MPG.0b013e318292fa0d (2013).
51. Manichanh, C. et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Research 20, 1411-1419, doi: 10.1101/gr.107987.110 (2010).
52. Joossens, M. et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut, doi: 10.1136/gut.2010.223263 (2011).
53. Lawley, T. D. et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8, e1002995, doi: 10.1371/journal.ppat.1002995 (2012).
54. McLaughlin, S. D., Clark, S. K., Tekkis, P. P., Ciclitira, P. J. & Nicholls, R. J. Review article: restorative proctocolectomy, indications, management of complications and follow-up - a guide for gastroenterologists. Alimentary Pharmacology & Therapeutics 27, 895-909, doi: 10.1111/j.1365-2036.2008.03643.x (2008).
55. McLaughlin, S. D. et al. Fecal Coliform Testing to Identify Effective Antibiotic Therapies for Patients With Antibiotic-Resistant Pouchitis. Clinical Gastroenterology and Hepatology 7, 545-548, doi: 10.1016/j.cgh.2009.01.002 (2009).
56. Cooper, P. et al. Patent human infections with the whipworm, Trichuris trichiura, are not associated with alterations in the faecal microbiota. PLoS One 8, e76573, doi: 10.1371/journal.pone.0076573 (2013).
57. Schloss, P. D. et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities. Applied and Environmental Microbiology 75, 7537-7541, doi: 10.1128/aem.01541-09 (2009).
58. White, J. R., Nagarajan, N. & Pop, M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 5, e1000352, doi: 10.1371/journal.pcbi.1000352 (2009).
59. Y. Benjamini & Y. H. Y. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B57, 289-300 (1995).
60. Bell, S. J. et al. Migration and maturation of human colonic dendritic cells. J Immunol 166, 4958-4967 (2001).
61. Al-Hassi, H. O. et al. A mechanistic role for leptin in human dendritic cell migration: differences between ileum and colon in health and Crohn's disease. Mucosal Immunology 6, 751-761, doi: 10.1038/mi.2012.113 (2012).
62. Panoskaltsis, N. P., Reid, C. D. P. & Knight, S. C. P. Quantification and cytokine production of circulating lymphoid and myeloid cells \par in acute myelogenous leukaemia.\par. Leukemia\par 17\par, 716-730\par, doi: 10.1038/sj.leu.2402835 (2003).
63. Bagwell, B. A journey through flow cytometric immunofluorescence analyses. Clinical Immunology Newsletter 16, 33-37 (1996).